4 recruiting, 3 not yet recruiting, 1 completed, 1 unknown. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Not yet recruiting 3, Completed 1, Unknown 1 |
Follow EGFR: new trials by email Literature Review of EGFR trials Research Report on EGFR
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC Zipalertinib - EGFR, Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Stanford University | 42 | 2026-11-01 | 2026-09-03 |
| Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC Firmonertinib combined anlotinib and chemotehrapy - NSCLC (Non-small Cell Lung Cancer), EGFR | Phase 2 | Not yet recruiting | Hubei Cancer Hospital | 29 | 2026-09-21 | 2026-09-08 |
| Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Trilaciclib and Sacituzumab Tirumotecan - NSCLC (Advanced Non-small Cell Lung Cancer), EGFR | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 49 | 2025-12-08 | 2026-04-14 |
| Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC Fumetinib combined platinum-based double chemotherapy, Concurrent Radiochemotherapy - EGFR, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Recruiting | Peng Zhang | 160 | 2025-11-25 | 2026-08-03 |
| Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer Surgery, Osimertinib - Non-Small Cell Lung Cancer, EGFR | Phase 2 | Not yet recruiting | Jianxing He | 118 | 2025-09-08 | 2025-09-16 |
| Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI Befotertinib, Pemetrexed + Carboplatin - NSCLC, Adjuvant Drug Therapy | Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 28 | 2025-09-01 | 2025-09-30 |
| Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer Befotertinib combined Bevacizumab, Befotertinib combined platinum-based double chemotherapy - EGFR, Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Peng Zhang | 60 | 2024-11-07 | 2025-01-06 |
| Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules Cetuximab-IRDye800 - Lung Cancer, Video-assisted Thoracic Surgery | Phase 2 | Unknown | University of Turin, Italy | 25 | 2024-01-01 | 2024-01-25 |
| Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer BIBW 2992 - Non-Small Cell Lung Cancer, EGFR | Phase 2 | Completed | Instituto Nacional de Cancerologia de Mexico | 66 | 2012-01-01 | 2024-02-06 |
Carcinoma, Non-Small-Cell Lung (7) · Lung Neoplasms (2)
Lung Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Neoplasms (6)
Afatinib (1) · Carboplatin (1) · Cetuximab (1) · Chemoradiotherapy (1) · Pemetrexed (1) · Surgical Procedures, Operative (1) · osimertinib (1) · trilaciclib (1) · zipalertinib (1)
Peng Zhang (2) · Betta Pharmaceuticals Co., Ltd. (1) · Hubei Cancer Hospital (1) · Instituto Nacional de Cancerologia de Mexico (1) · Jianxing He (1) · Stanford University (1) · The First Affiliated Hospital of Xiamen University (1) · University of Turin, Italy (1)
China (5) · Italy (1) · Mexico (1)
DongYing Liu (1) · Enrico Ruffini, M.D. (1) · Francesco Guerrera, M.D., Ph.D. (1) · GuiNan Lin (1) · Joel Neal, MD (1) · Oscar Arrieta, MD M Sc (1) · Shaodong Hong (1) · XiaoFeng Pei (1) · YingNi Lian (1)